Valuation: Lundbeck

Market Cap 45.13B 6.76B 6.03B 5.61B 5.11B 9.64B 655B 9.68B 67.48B 26.44B 333B 25.4B 24.84B 1,070B P/E 2026 *
10.2x
P/E 2027 * 9.93x
Enterprise Value 49.13B 7.36B 6.57B 6.11B 5.56B 10.49B 713B 10.54B 73.47B 28.79B 363B 27.65B 27.04B 1,165B EV / Sales 2026 *
1.9x
EV / Sales 2027 * 1.72x
Free-Float
30.74%
Yield 2026 *
3.38%
Yield 2027 * 3.04%
1 day-0.11%
1 week+6.31%
Current month+2.58%
1 month+0.69%
3 months+19.35%
6 months+30.75%
Current year+20.99%
1 week 41.85
Extreme 41.85
44.4
1 month 38.75
Extreme 38.75
45
Current year 31.4
Extreme 31.4
45
1 year 31.4
Extreme 31.4
45
3 years 23.3
Extreme 23.3
45
5 years 21.94
Extreme 21.935
45
10 years 21.94
Extreme 21.935
45
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 67 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+6.31% - - 6.78B
+0.83%+2.56%+39.44%+108.64% 1,043B
+1.93%+1.07%+37.82%+65.85% 618B
+1.49%+6.36%+19.56%+86.50% 481B
+2.26%+1.24%+68.52%+40.16% 351B
+1.45%+2.52%+22.83%+44.22% 338B
+1.17%+0.88%+11.83%+34.76% 269B
+0.89%-0.28%-6.31%+9.65% 244B
+1.82%+1.87%+40.82%+55.11% 220B
+2.77%+2.49%+27.84%+102.26% 182B
Average +0.77%+0.28%+29.15%+60.79% 416.3B
Weighted average by Cap. +0.68%+0.60%+32.41%+71.30%

Financials

2026 *2027 *
Net sales 25.86B 3.88B 3.46B 3.22B 2.93B 5.52B 375B 5.55B 38.67B 15.15B 191B 14.55B 14.23B 613B 26.09B 3.91B 3.49B 3.25B 2.95B 5.57B 378B 5.6B 39.02B 15.29B 193B 14.68B 14.36B 619B
Net income 4.57B 684M 610M 568M 517M 975M 66.24B 980M 6.83B 2.68B 33.72B 2.57B 2.51B 108B 4.62B 692M 617M 575M 523M 986M 67B 991M 6.91B 2.71B 34.11B 2.6B 2.54B 110B
Net Debt 4B 600M 535M 498M 453M 855M 58.06B 859M 5.99B 2.35B 29.56B 2.25B 2.2B 94.92B -182M -27.25M -24.3M -22.61M -20.59M -38.82M -2.64B -38.99M -272M -107M -1.34B -102M -100M -4.31B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-10-09 DKK 43.80 -0.11% 26,901
26-10-08 DKK 43.85 +0.92% 47,409
26-10-07 DKK 43.45 +0.58% 33,353
26-10-06 DKK 43.20 +1.41% 59,317
26-10-05 DKK 42.60 +2.16% 38,048
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
45.96DKK
Average target price
49.19DKK
Spread / Average Target
+7.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck